Paradigm Biopharmaceuticals Limited (P86.F)
- Previous Close
0.1530 - Open
0.1690 - Bid 0.1700 x --
- Ask 0.1840 x --
- Day's Range
0.1690 - 0.1690 - 52 Week Range
0.1030 - 0.3600 - Volume
4,000 - Avg. Volume
132 - Market Cap (intraday)
76.725M - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
www.paradigmbiopharma.comRecent News: P86.F
View MorePerformance Overview: P86.F
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: P86.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: P86.F
View MoreValuation Measures
Market Cap
62.22M
Enterprise Value
48.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.12
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.14%
Return on Equity (ttm)
-42.91%
Revenue (ttm)
16.7k
Net Income Avi to Common (ttm)
-14.56M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
24.78M
Total Debt/Equity (mrq)
0.53%
Levered Free Cash Flow (ttm)
-21.8M